Congressmen Call for Report on New Class of Drugs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Congressmen Call for Report on New Class of Drugs


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Washington DC (Jan. 21)—Congressmen John Dingell (D-MI) and Bart Stupak (D-MI) have requested that the Government Accountability Office (GAO) perform an updated assessment in response to the US Food and Drug Administration’s potential development of a new class of behind-the-counter (BTC) drugs, according to the Jan. 21 edition of Drug Industry Daily.

In a letter to GAO Comptroller General David Walker, the congressmen requested that more information be gathered in order to assess the benefits, risks, and general necessity of any new class of BTC drugs. In an August 1995 report, GOA evaluated the experience of other countries with BTC drugs, and found insufficient evidence to support the establishment of a new class of BTC drugs in the United States. The US representatives’ letter to Walker suggested that the gathering of new data was necessary; however, the new report would not have to include an investigation of other countries with similar BTC drug programs.

According to Drug Industry Daily, the potential new class of drugs being evaluated by FDA would be those drugs deemed to not require a doctor’s prescription but would need the approval of a pharmacist to purchase. Although no FDA proposal has been presented regarding the creation of a new class of BTC drugs, opponents suggest the new class may raise drug costs. Supporters of BTC drugs suggest that today’s patients are more informed about their health and that an individual’s access to drugs would improve without the need of a doctor’s prescription.

The potential new class of BTC drugs could include oral contraceptives, over-the-counter children’s cough and cold medicines, Tamiflu, and epinephrine injections.

Rep. Dingell is the Chairman of the House Committee on Energy and Commerce and Rep. Stupak is the Chairman of the Oversight and Investigations Subcommittee.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
25%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
36%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here